Peptides and peptidomimetics in combination with T cell activating and/or checkpoint inhibiting agents for cancer treatment
US2017112894A1
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
WO2015178508A1
Nrf2-based cancer treatment and detection methods and uses
SG11201510490VA
Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations
AU2008294410A1
Compounds with anti-cancer activity
EP1664340A1
Sensitivity test to predict efficacy of anti-cancer therapies
KR20060065588A
Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
CN1798570A
Anti-fungal compounds and methods of use
US7125842B2
Anti-fungal compounds and methods of use
CN1671644A
The cell cycle G2 outpost of the tax office that the elimination dna damage causes and/or the compound that strengthens dna damage treatment antitumour activity
CA2471192A1
Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
US6881575B1
Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents
JP2001157585A
Enhancer for anticancer therapy and method for screening the enhancer
